JP2018532689A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018532689A5 JP2018532689A5 JP2018502118A JP2018502118A JP2018532689A5 JP 2018532689 A5 JP2018532689 A5 JP 2018532689A5 JP 2018502118 A JP2018502118 A JP 2018502118A JP 2018502118 A JP2018502118 A JP 2018502118A JP 2018532689 A5 JP2018532689 A5 JP 2018532689A5
- Authority
- JP
- Japan
- Prior art keywords
- functional fragment
- radiolabeled
- seq
- composition according
- vhh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 32
- 238000000034 method Methods 0.000 claims 22
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 201000011510 cancer Diseases 0.000 claims 10
- 238000003384 imaging method Methods 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 6
- 238000012216 screening Methods 0.000 claims 6
- 230000002285 radioactive effect Effects 0.000 claims 5
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical group [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 claims 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 4
- 229960002087 pertuzumab Drugs 0.000 claims 4
- 238000011287 therapeutic dose Methods 0.000 claims 3
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 238000013170 computed tomography imaging Methods 0.000 claims 2
- RYGMFSIKBFXOCR-AKLPVKDBSA-N copper-67 Chemical compound [67Cu] RYGMFSIKBFXOCR-AKLPVKDBSA-N 0.000 claims 2
- 235000018417 cysteine Nutrition 0.000 claims 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- 229940022353 herceptin Drugs 0.000 claims 2
- AMZMQXJQIYKBJU-UHFFFAOYSA-N iodo benzoate Chemical compound IOC(=O)C1=CC=CC=C1 AMZMQXJQIYKBJU-UHFFFAOYSA-N 0.000 claims 2
- 238000002595 magnetic resonance imaging Methods 0.000 claims 2
- 238000012633 nuclear imaging Methods 0.000 claims 2
- 238000002600 positron emission tomography Methods 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 claims 2
- 238000002603 single-photon emission computed tomography Methods 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562193700P | 2015-07-17 | 2015-07-17 | |
| US62/193,700 | 2015-07-17 | ||
| EP16153372 | 2016-01-29 | ||
| EP16153372.4 | 2016-01-29 | ||
| PCT/EP2016/066934 WO2017013026A1 (en) | 2015-07-17 | 2016-07-15 | Radiolabelled antibody fragments for use in treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018532689A JP2018532689A (ja) | 2018-11-08 |
| JP2018532689A5 true JP2018532689A5 (enExample) | 2019-05-16 |
| JP6917357B2 JP6917357B2 (ja) | 2021-08-11 |
Family
ID=57833837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018502118A Active JP6917357B2 (ja) | 2015-07-17 | 2016-07-15 | 癌治療に使用する放射標識抗体断片 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11298433B2 (enExample) |
| EP (1) | EP3325020B1 (enExample) |
| JP (1) | JP6917357B2 (enExample) |
| KR (2) | KR20250174696A (enExample) |
| CN (1) | CN108025093B (enExample) |
| AU (1) | AU2016294858B2 (enExample) |
| CA (1) | CA2991398A1 (enExample) |
| MX (1) | MX390949B (enExample) |
| WO (1) | WO2017013026A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109096401B (zh) * | 2017-06-20 | 2021-07-27 | 和迈生物科技有限公司 | 抗Her2纳米抗体及其编码序列和用途 |
| EP3967674A1 (en) * | 2020-09-11 | 2022-03-16 | Precirix N.V. | Reactions of radioactive compounds facilitated by a solid phase |
| CN112561871B (zh) * | 2020-12-08 | 2021-09-03 | 中国医学科学院北京协和医院 | 一种基于平扫ct图像的主动脉夹层分割方法和装置 |
| CN117321081A (zh) * | 2021-02-22 | 2023-12-29 | 雅博得乐医疗公司 | 用于靶向放射性同位素疗法的免疫缀合物 |
| AU2023276697A1 (en) * | 2022-05-23 | 2024-12-12 | Cereius, Inc. | Her2-binding agents and uses thereof |
| CN121293357A (zh) | 2022-08-22 | 2026-01-09 | 雅博得乐医疗公司 | Dll3结合分子及其用途 |
| CN116719074A (zh) * | 2023-05-29 | 2023-09-08 | 中国核电工程有限公司 | 一种两栖生物辐射剂量率的获取方法及装置 |
| WO2025034806A1 (en) | 2023-08-08 | 2025-02-13 | Wisconsin Alumni Research Foundation | Single-domain antibodies and variants thereof against fibroblast activation protein |
| WO2026008881A1 (en) | 2024-07-05 | 2026-01-08 | Synaffix B.V. | Extracellular vesicles comprising biomolecule-conjugates |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE203767T1 (de) | 1992-08-21 | 2001-08-15 | Univ Bruxelles | Immunoglobuline ohne leichte ketten |
| ATE204325T1 (de) | 1993-04-29 | 2001-09-15 | Unilever Nv | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| FR2708622B1 (fr) | 1993-08-02 | 1997-04-18 | Raymond Hamers | Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides. |
| WO1996008565A2 (en) | 1994-09-16 | 1996-03-21 | Cancer Research Fund Of Contra Costa | RECOMBINANT PEPTIDES DERIVED FROM THE Mc3 ANTI-BA46 ANTIBODY, METHODS OF USE THEREOF, AND METHODS OF HUMANIZING ANTIBODY PEPTIDES |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| ES2294799T3 (es) | 1996-06-27 | 2008-04-01 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana. |
| BR9907241A (pt) | 1998-01-26 | 2000-10-17 | Unilever Nv | Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo |
| BR9916765A (pt) | 1999-01-05 | 2001-09-25 | Unilever Nv | Processo para produzir um material imunoadsorvente, uso de uma proteìna que é ligada por meio de uma ligação covalente a um fragmento de anticorpo, material imunadsorvente, uso de um material, e, kit de teste diagnóstico |
| DE60013767T3 (de) | 1999-01-19 | 2009-07-09 | Unilever N.V. | Verfahren zur herstellung von antikörperfragmenten |
| WO2000065057A1 (en) | 1999-04-22 | 2000-11-02 | Unilever Plc | Inhibition of viral infection using monovalent antigen-binding proteins |
| US6479280B1 (en) | 1999-09-24 | 2002-11-12 | Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw | Recombinant phages capable of entering host cells via specific interaction with an artificial receptor |
| US7358096B1 (en) | 1999-11-29 | 2008-04-15 | Conopco, Inc. | Immobilisation of proteins |
| DK1233987T3 (da) | 1999-11-29 | 2009-09-28 | Bac Ip B V | Immobiliserede enkelt-domæne antigenbindende molekyler |
| ES2324280T3 (es) | 2000-03-14 | 2009-08-04 | Unilever N.V. | Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos. |
| WO2001090190A2 (en) | 2000-05-26 | 2001-11-29 | National Research Council Of Canada | Single-domain antigen-binding antibody fragments derived from llama antibodies |
| WO2002048193A2 (en) | 2000-12-13 | 2002-06-20 | Unilever N.V. | Camelidae antibody arrays |
| JP4213586B2 (ja) | 2001-09-13 | 2009-01-21 | 株式会社抗体研究所 | ラクダ抗体ライブラリーの作製方法 |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| AU2002351896A1 (en) | 2001-12-11 | 2003-06-23 | Ablynx N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
| US20050037358A1 (en) | 2001-12-21 | 2005-02-17 | Serge Muyldermans | Method for cloning of variable domain sequences |
| CA2471645A1 (en) | 2002-01-03 | 2003-07-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Immunoconjugates useful for treatment of tumours |
| BRPI0316092B8 (pt) | 2002-11-08 | 2021-05-25 | Ablynx Nv | anticorpos de domínio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos |
| EP2284192A3 (en) | 2002-11-08 | 2011-07-20 | Ablynx N.V. | Camelidae antibodies for sublingual administration |
| RU2357974C2 (ru) | 2003-01-10 | 2009-06-10 | Аблинкс Н.В. | Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами |
| US20090304590A1 (en) | 2007-05-29 | 2009-12-10 | Wyeth | Therapeutic compositions and methods |
| CA2706425A1 (en) * | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
| EP2143735A1 (en) | 2008-07-10 | 2010-01-13 | Institut Pasteur | Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins |
| WO2010042815A2 (en) | 2008-10-09 | 2010-04-15 | Duke University | Vhh antibody fragments for use in the detection and treatment of cancer |
| US10517969B2 (en) * | 2009-02-17 | 2019-12-31 | Cornell University | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
| WO2011051327A2 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
| EP2807189B1 (en) | 2012-01-23 | 2019-03-20 | Ablynx N.V. | Sequences directed against hepatocyte growth factor (hgf) and polypeptides comprising the same for the treatment of cancers and/or tumors |
| CA2906259C (en) | 2013-03-15 | 2022-12-06 | Vib Vzw | Anti-mmr single variable domains for prognosis and monitoring of cardiovascular diseases |
| EP3008093A1 (en) * | 2013-06-11 | 2016-04-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer |
| WO2015073746A2 (en) | 2013-11-13 | 2015-05-21 | Whitehead Institute For Biomedical Research | 18f labeling of proteins using sortases |
| EP3174559B1 (en) | 2014-07-29 | 2022-10-19 | Vrije Universiteit Brussel | Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer |
| EP3180037A1 (en) * | 2014-07-29 | 2017-06-21 | Vrije Universiteit Brussel | Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response |
-
2016
- 2016-07-15 WO PCT/EP2016/066934 patent/WO2017013026A1/en not_active Ceased
- 2016-07-15 MX MX2018000598A patent/MX390949B/es unknown
- 2016-07-15 JP JP2018502118A patent/JP6917357B2/ja active Active
- 2016-07-15 US US15/742,161 patent/US11298433B2/en active Active
- 2016-07-15 AU AU2016294858A patent/AU2016294858B2/en active Active
- 2016-07-15 CA CA2991398A patent/CA2991398A1/en active Pending
- 2016-07-15 CN CN201680053382.1A patent/CN108025093B/zh active Active
- 2016-07-15 EP EP16745643.3A patent/EP3325020B1/en active Active
- 2016-07-15 KR KR1020257039216A patent/KR20250174696A/ko active Pending
- 2016-07-15 KR KR1020187001952A patent/KR20180042226A/ko not_active Ceased
-
2022
- 2022-03-11 US US17/692,315 patent/US12440586B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018532689A5 (enExample) | ||
| Tolmachev | Imaging of HER-2 overexpression in tumors for guiding therapy | |
| Tolmachev et al. | Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy | |
| Sugiura et al. | Radiolabeling strategies for tumor-targeting proteinaceous drugs | |
| Zhang et al. | Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA | |
| US20250345466A1 (en) | Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy | |
| Rinne et al. | PET and SPECT imaging of the EGFR family (RTK class I) in oncology | |
| JP2020512281A5 (enExample) | ||
| JP6917357B2 (ja) | 癌治療に使用する放射標識抗体断片 | |
| Tolmachev et al. | Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels | |
| Persson et al. | [177Lu] pertuzumab: experimental studies on targeting of HER-2 positive tumour cells | |
| Reddy et al. | Immuno-positron emission tomography in cancer models | |
| JP2016528299A5 (enExample) | ||
| Lindegren et al. | Binding affinity, specificity and comparative biodistribution of the parental murine monoclonal antibody MX35 (Anti-NaPi2b) and its humanized version Rebmab200 | |
| Walther et al. | Implementation of 89Zr production and in vivo imaging of B-cells in mice with 89Zr-labeled anti-B-cell antibodies by small animal PET/CT | |
| JP7688941B2 (ja) | Ｃｄ８結合ポリペプチドおよびその使用 | |
| Sarcan et al. | Monoclonal antibodies and immuno-PET imaging: An overview | |
| Wållberg et al. | Design and evaluation of radiolabeled tracers for tumor imaging | |
| Wållberg et al. | Evaluation of the radiocobalt-labeled [MMA-DOTA-Cys61]-ZHER2: 2395-Cys affibody molecule for targeting of HER2-expressing tumors | |
| Salsano et al. | PET imaging using radiolabelled antibodies: future direction in tumor diagnosis and correlate applications | |
| Niu et al. | Molecular imaging of human epidermal growth factor receptor 2 (HER-2) expression | |
| Kong et al. | Managing Lymphoma with Non‐FDG Radiotracers: Current Clinical and Preclinical Applications | |
| JP2009292815A (ja) | 腫瘍診断に使用するための抗−Ｍｅｔモノクローナル抗体、そのフラグメントおよび誘導体、対応する組成物およびキット | |
| Suman et al. | Synthesis and preliminary evaluation of 99mTc-Hynic-fragments [F (ab') 2 and F (ab')] of Rituximab as radioimmunoscintigraphic agents for patients with Non-Hodgkin's lymphoma | |
| CA3163311A1 (en) | Multimodal fluorine-cy3/5/7-dota-hapten compositions, diagnostics, fluorescence guided surgery and radioimmunotherapy |